Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Gilead Sciences
Biotech
Gilead blames low infection rates for ending 2 RSV trials
Gilead has blamed the low rate of respiratory syncytial virus infections last season for ending two midstage trials of obeldesivir.
James Waldron
Jun 27, 2025 4:09am
Kymera suffers Sanofi setback but secures $750M Gilead deal
Jun 25, 2025 9:31am
Gilead lays off 36 people after axing Oceanside expansion plan
Jun 16, 2025 9:53am
How 'overenthusiasm' led to Big Pharma's risky $6B TIGIT gamble
Jun 13, 2025 8:00am
FDA slaps clinical hold on multiple Gilead HIV trials
Jun 10, 2025 10:48am
To Gilead's new CMO, pipeline diversification is key
Jun 9, 2025 10:00am
